WO2002017962A3 - Agent de chimio-prevention contre la toxicite gastrique - Google Patents

Agent de chimio-prevention contre la toxicite gastrique Download PDF

Info

Publication number
WO2002017962A3
WO2002017962A3 PCT/US2001/027296 US0127296W WO0217962A3 WO 2002017962 A3 WO2002017962 A3 WO 2002017962A3 US 0127296 W US0127296 W US 0127296W WO 0217962 A3 WO0217962 A3 WO 0217962A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemoprotectant
gastric toxicity
agent
administering
cytotoxic
Prior art date
Application number
PCT/US2001/027296
Other languages
English (en)
Other versions
WO2002017962A9 (fr
WO2002017962A2 (fr
Inventor
Edward A Neuwelt
Leslie Muldoon
Original Assignee
Univ Oregon Health & Science
Edward A Neuwelt
Leslie Muldoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Edward A Neuwelt, Leslie Muldoon filed Critical Univ Oregon Health & Science
Priority to CA002420897A priority Critical patent/CA2420897A1/fr
Priority to EP01966515A priority patent/EP1365803A2/fr
Priority to AU2001287021A priority patent/AU2001287021A1/en
Priority to US10/363,150 priority patent/US20040062764A1/en
Publication of WO2002017962A2 publication Critical patent/WO2002017962A2/fr
Publication of WO2002017962A9 publication Critical patent/WO2002017962A9/fr
Publication of WO2002017962A3 publication Critical patent/WO2002017962A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode et une composition pharmaceutique destinées au traitement ou à l'atténuation des effets secondaires de la chimiothérapie cytotoxique utilisée contre les tumeurs cancéreuses. Cette méthode consiste à administrer un agent de chimio-prévention à base de thiols et un agent cytotoxique comportant un moyen de ciblage des glycoprotéines de Lewis Y.
PCT/US2001/027296 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique WO2002017962A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002420897A CA2420897A1 (fr) 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique
EP01966515A EP1365803A2 (fr) 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique
AU2001287021A AU2001287021A1 (en) 2000-08-30 2001-08-30 Chemoprotectant for gastric toxicity
US10/363,150 US20040062764A1 (en) 2001-08-30 2001-08-30 Chemoprotectant for gastric toxicity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22986900P 2000-08-30 2000-08-30
US60/229,869 2000-08-30

Publications (3)

Publication Number Publication Date
WO2002017962A2 WO2002017962A2 (fr) 2002-03-07
WO2002017962A9 WO2002017962A9 (fr) 2003-03-27
WO2002017962A3 true WO2002017962A3 (fr) 2003-07-10

Family

ID=22862985

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/027296 WO2002017962A2 (fr) 2000-08-30 2001-08-30 Agent de chimio-prevention contre la toxicite gastrique

Country Status (4)

Country Link
EP (1) EP1365803A2 (fr)
AU (1) AU2001287021A1 (fr)
CA (1) CA2420897A1 (fr)
WO (1) WO2002017962A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040229815A1 (en) * 2003-01-03 2004-11-18 Nagasawa Herbert T. Methods for reducing oxidative stress in a cell with a sulfhydryl protected glutathione prodrug
US20040198841A1 (en) * 2003-03-13 2004-10-07 Oregon Health & Science University Use of thiol-based compositions in ameliorating mucosal injury
WO2005070026A2 (fr) * 2004-01-23 2005-08-04 Seattle Genetics, Inc. Polytherapie d'immunoconjugues medicamenteux
US20060008415A1 (en) * 2004-06-25 2006-01-12 Protein Design Labs, Inc. Stable liquid and lyophilized formulation of proteins
EP2881833B1 (fr) 2013-12-09 2019-06-19 Batz, S.Coop. Pédale réglable pour véhicules à moteur
WO2016044716A1 (fr) * 2014-09-19 2016-03-24 The American University In Cairo Polythérapie à base de nanoparticules

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624377A2 (fr) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Conjugués antitumoraux divables pour enzyme lysosomiales
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0624377A2 (fr) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Conjugués antitumoraux divables pour enzyme lysosomiales
US5994409A (en) * 1997-12-09 1999-11-30 U.S. Bioscience, Inc. Methods for treatment of neuro--and nephro--disorders and therapeutic toxicities using aminothiol compounds

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
REMSEN L G ET AL: "Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model.", NEUROSURGERY, (2000 MAR) 46 (3) 704-9., XP008010030 *
TRAIL P A ET AL: "Enhanced antitumor activity of paclitaxel in combination with the anticarcinoma immunoconjugate BR96 - doxorubicin.", CLINICAL CANCER RESEARCH, (1999 NOV) 5 (11) 3632-8., XP002203755 *
TRESKES, MARCO (1) ET AL: "WR2721 as a modulator of cisplatin - and carboplatin-induced side effects in comparison with other chemoprotective agents: A molecular approach.", CANCER CHEMOTHERAPY AND PHARMACOLOGY, (1993) VOL. 33, NO. 2, PP. 93-106., XP002053093 *
UOZUMI J ET AL: "Effectiveness of "two-route chemotherapy" using cisplatin and its antidote, sodium thiosulfate, on lifespan of rats bearing metastatic liver tumors.", CANCER TREATMENT REPORTS, (1983 DEC) 67 (12) 1067-74., XP008010094 *

Also Published As

Publication number Publication date
AU2001287021A1 (en) 2002-03-13
WO2002017962A9 (fr) 2003-03-27
CA2420897A1 (fr) 2002-03-07
WO2002017962A2 (fr) 2002-03-07
EP1365803A2 (fr) 2003-12-03

Similar Documents

Publication Publication Date Title
CA2301057A1 (fr) Procede permettant d'administrer un taxane liposomal encapsule
MXPA02011913A (es) Triazolopirimidinas sustituidas como agentes anticancer.
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
CA2418479A1 (fr) Promedicaments de derives de l'acide betulinique pour le traitement du cancer et du vih
EP1154782A4 (fr) Derives de taxane pour therapie ciblee contre le cancer
EP0954340A4 (fr) Immunotherapie-cible associee contre le cancer
TR200200717T2 (tr) Terapötik kinazolin türevleri.
UA49787C2 (uk) Спосіб підвищення цитотоксичності хіміотерапевтичного агента та спосіб підвищення цитотоксичності днк-алкілувального хіміотерапевтичного агента
WO2001080832A3 (fr) Administration d'un compose chimioprotecteur a base de thiol
HK1046093A1 (en) Docetaxel in combination with rhumab her2 for the treatment of cancers.
TW362971B (en) Pharmaceutical composition and kit for treating cancer by conjunctive therapy with 2'-halomethylidene derivatives and a S-phase or M-phase specific anti
WO2002002147A3 (fr) Isolement d'un peptide d'internalisation specifique des cellules infiltrant les tissus tumoraux pour liberation medicamenteuse ciblee
WO2004045593A3 (fr) Polytherapie anticancereuse au moyen d'un compose anticancereux active par gst et d'un autre traitement anticancereux
NZ504938A (en) Tumor antigen peptide derivatives capable of binding to HLA-A24 antigen
WO1993007866A3 (fr) Compositions et procedes de traitement et de prevention du cancer, du sida, et de l'anemie
AU6369900A (en) Aromatic esters of camptothecins and methods to treat cancers
AU2003217982A1 (en) Botanical extract compositions with anti-cancer or phytoestrogenic activity comprising wogonin, isoliquiritigenin and/or coumestrol
EP1545479A4 (fr) Compositions d'ezetimibe, et procedes pour le traitement de tumeurs benignes et malignes associees au cholesterol
CA3198996A1 (fr) Conjugues anticorps-medicament inhibiteurs de bcl-xl et leurs procedes d'utilisation
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat
WO2002017962A3 (fr) Agent de chimio-prevention contre la toxicite gastrique
AU2162202A (en) Antitumor therapy comprising distamycin derivatives
WO2000006136A3 (fr) METHODE PERMETTANT DE TRAITER LE CANCER CHEZ DES PATIENTS PRESENTANT UNE DEFICIENCE DU SUPPRESSEUR DE TUMEUR p53
GEP20043254B (en) Use of Camptothecin Derivatives with Reduced Gastrointestinal Toxicity
EP1003516A4 (fr) Administration de composes camptotheciniques de cancerotherapie avec reduction de leurs effets secondaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2420897

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001966515

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/6-6/6, DRAWINGS, REPLACED BY NEW PAGES 1/6-6/6; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10363150

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2001966515

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001966515

Country of ref document: EP